東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Development of VSV-based SARS vaccin...

Yale University.

FindBook

Google Book

Amazon

博客來

Development of VSV-based SARS vaccine vectors.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Development of VSV-based SARS vaccine vectors./
作者:	Kapadia, Sagar Umesh.
面頁冊數:	113 p.
附註:	Adviser: John K. Rose.
Contained By:	Dissertation Abstracts International69-05B.
標題:	Biology, Virology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3317140
ISBN:	9780549658849

Development of VSV-based SARS vaccine vectors.
Kapadia, Sagar Umesh.

Development of VSV-based SARS vaccine vectors. - 113 p.

Adviser: John K. Rose.

Thesis (Ph.D.)--Yale University, 2008.

The SARS outbreak was the first infectious disease of the 21st century to grab global attention. Although it was contained by 2003, the chance of a reemergence is probable because meat markets that expose humans to animals carrying the coronavirus that causes SARS (SARS-CoV) are still operational. Because of a this risk and because of the high death rate associated with SARS, a vaccine would be a useful tool for protection in the event of another outbreak. Therefore, we developed a recombinant VSV-based SARS vaccine using the S protein of SARS-CoV as an antigen. We found that in a mouse model a single dose of the vaccine was able to induce a neutralizing antibody response and protect against SARS-CoV infection. Furthermore, we determined that an antibody response was sufficient for this protection. In order to address safety concerns affiliated with a live viral vaccine, we next attenuated our SARS vaccine so that it could only undergo one round of replication. Such a replication-deficient virus would also allow for quick regulatory approval. We found that one dose of this single-cycle vaccine was able to induce a strong neutralizing antibody response that was indicative of protection. We next constructed and characterized various other potential VSV-based SARS vaccines using other SARS-CoV antigens, M, 3a, N and E. Finally, in an effort to minimize potential exposure to SARS-CoV in the laboratory, we developed a VSV-based pseudotype that can substitute for the SARS-CoV in neutralization assays. Unlike, SARS-CoV, this pseudotype does not require biosafety level 3 containment.

ISBN: 9780549658849Subjects--Topical Terms:

1019068
Biology, Virology.

Development of VSV-based SARS vaccine vectors.
LDR:02440nam 2200277 a 45 001 855206
005 20100708
008 100708s2008 ||||||||||||||||| ||eng d
020 $a 9780549658849
035 $a (UMI)AAI3317140
035 $a AAI3317140
040 $a UMI $c UMI
100 1 $a Kapadia, Sagar Umesh. $3 1021751
245 1 0 $a Development of VSV-based SARS vaccine vectors.
300 $a 113 p.
500 $a Adviser: John K. Rose.
500 $a Source: Dissertation Abstracts International, Volume: 69-05, Section: B, page: 2841.
502 $a Thesis (Ph.D.)--Yale University, 2008.
520 $a The SARS outbreak was the first infectious disease of the 21st century to grab global attention. Although it was contained by 2003, the chance of a reemergence is probable because meat markets that expose humans to animals carrying the coronavirus that causes SARS (SARS-CoV) are still operational. Because of a this risk and because of the high death rate associated with SARS, a vaccine would be a useful tool for protection in the event of another outbreak. Therefore, we developed a recombinant VSV-based SARS vaccine using the S protein of SARS-CoV as an antigen. We found that in a mouse model a single dose of the vaccine was able to induce a neutralizing antibody response and protect against SARS-CoV infection. Furthermore, we determined that an antibody response was sufficient for this protection. In order to address safety concerns affiliated with a live viral vaccine, we next attenuated our SARS vaccine so that it could only undergo one round of replication. Such a replication-deficient virus would also allow for quick regulatory approval. We found that one dose of this single-cycle vaccine was able to induce a strong neutralizing antibody response that was indicative of protection. We next constructed and characterized various other potential VSV-based SARS vaccines using other SARS-CoV antigens, M, 3a, N and E. Finally, in an effort to minimize potential exposure to SARS-CoV in the laboratory, we developed a VSV-based pseudotype that can substitute for the SARS-CoV in neutralization assays. Unlike, SARS-CoV, this pseudotype does not require biosafety level 3 containment.
590 $a School code: 0265.
650 4 $a Biology, Virology. $3 1019068
650 4 $a Health Sciences, Immunology. $3 1017716
690 $a 0720
690 $a 0982
710 2 $a Yale University. $3 515640
773 0 $t Dissertation Abstracts International $g 69-05B.
790 $a 0265
790 1 0 $a Rose, John K., $e advisor
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3317140